HAVCR2 and ovarian cancer: In view of recent encouraging results of immunomodulatory mAbs in clinic for treatment of multiple solid tumor [43], our finding that TIM-3 blockade and CD137 activation synergistically induce a potent antitumor effect in a highly clinical relevant ID8 ovarian cancer model should aid the design of future trials for ovarian cancer immunotherapy.